{"disease":{"id":"metastatic-and-advanced-solid-tumors","name":"metastatic and advanced solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07156253","title":"Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT02452268","title":"A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03684785","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Exicure, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}